Triple

T11306661
Position Surface form Disambiguated ID Type / Status
Subject Novato, California E267730 entity
Predicate hasEmployer P7 FINISHED
Object BioMarin Pharmaceutical
BioMarin Pharmaceutical is a biotechnology company specializing in developing and commercializing therapies for rare genetic diseases.
E917097 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: BioMarin Pharmaceutical | Statement: [Novato, California, hasEmployer, BioMarin Pharmaceutical]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: BioMarin Pharmaceutical
Context triple: [Novato, California, hasEmployer, BioMarin Pharmaceutical]
  • A. Biogen
    Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
  • B. Amgen
    Amgen is a leading American biopharmaceutical company known for developing innovative therapies in areas such as oncology, nephrology, and inflammatory diseases.
  • C. Genzyme
    Genzyme is a biotechnology company best known for developing treatments for rare genetic disorders and other specialty diseases.
  • D. Alnylam Pharmaceuticals
    Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
  • E. Regeneron Pharmaceuticals
    Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: BioMarin Pharmaceutical
Triple: [Novato, California, hasEmployer, BioMarin Pharmaceutical]
Generated description
BioMarin Pharmaceutical is a biotechnology company specializing in developing and commercializing therapies for rare genetic diseases.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: BioMarin Pharmaceutical
Target entity description: BioMarin Pharmaceutical is a biotechnology company specializing in developing and commercializing therapies for rare genetic diseases.
  • A. Biogen
    Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
  • B. Amgen
    Amgen is a leading American biopharmaceutical company known for developing innovative therapies in areas such as oncology, nephrology, and inflammatory diseases.
  • C. Genzyme
    Genzyme is a biotechnology company best known for developing treatments for rare genetic disorders and other specialty diseases.
  • D. Alnylam Pharmaceuticals
    Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
  • E. Regeneron Pharmaceuticals
    Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d6aaca5c24819083db46a30d86cb34 completed April 8, 2026, 7:21 p.m.
NER Named-entity recognition batch_69d7e9a7255c81909675fe9ad6d71934 completed April 9, 2026, 6:02 p.m.
NED1 Entity disambiguation (via context triple) batch_69e50a62ceec8190af25edf44c5fc1e9 completed April 19, 2026, 5:01 p.m.
NEDg Description generation batch_69e510fb1e288190a7a38fe896d7b91d completed April 19, 2026, 5:29 p.m.
NED2 Entity disambiguation (via description) batch_69e516bec3e481909cbd0d9c683d2191 completed April 19, 2026, 5:54 p.m.
Created at: April 8, 2026, 9:32 p.m.